Treatment of growth hormone attenuates hepatic steatosis in hyperlipidemic mice via downregulation of hepatic CD36 expression

다국어 초록 (Multilingual Abstract)

The recombinant human growth hormone (GH) has been used for the treatment of growth hormone deficiency (GHD) and diverse short stature state, and its physiological and therapeutic effects are well documented. However, since the effect of GH treatment on metabolic disorders has not been well characterized, we injected GH to Western diet-fed low-density lipoprotein receptor-deficient (Ldlr−/−) mice to understand the exact effect of GH on metabolic diseases including atherosclerosis, hepatic steatosis, and obesity. Exogenous GH treatment increased plasma IGF-1 concentration and decreased body weight without affecting serum lipid profiles.
GH treatment changed neither atherosclerotic lesion size nor collagen and smooth muscle cells accumulation in the lesion. GH treatment reduced macrophage accumulation in adipose tissue.
Importantly, GH treatment attenuated hepatic steatosis and inflammation. The hepatic expression IL-1β mRNA were decreased by GH treatment. The mRNA and protein levels of CD36 were markedly decreased in GH treated mice without significant changes in other molecules related to lipid metabolism. Therefore, the treatment of GH treatment could attenuate hepatic steatosis and inflammation with downregulation of CD36 expression in hyperlipidemic condition.

참고문헌 (Reference)

1 Chishima S, "The relationship between the growth hormone/insulin-like growth factor system and the histological features of nonalcoholic fatty liver disease" 56 : 473-480, 2017

2 Rasmussen MH, "The impact of obesity, fat distribution, and energy restriction on insulin-like growth factor-1(IGF-1), IGF-binding protein-3, insulin, and growth hormone" 43 : 315-319, 1994

3 Juul A, "Serum levels of insulin-like growth factor I and its binding proteins in health and disease" 13 : 113-170, 2003

4 Kelley KW, "Protein hormones and immunity" 21 : 384-392, 2007

5 Hashimoto E, "Prevalence, gender, ethnic variations, and prognosis of NASH" 46 (46): 63-69, 2011

6 Rasmussen MH, "Obesity, growth hormone and weight loss" 316 : 147-153, 2010

7 Adams LA, "Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction" 39 : 909-914, 2004

8 Angulo P, "Nonalcoholic fatty liver disease" 346 : 1221-1231, 2002

9 Hong JW, "Metabolic parameters and nonalcoholic fatty liver disease in hypopituitary men" 43 : 48-54, 2011

10 Delafontaine P, "Insulin-like growth factor I and its binding proteins in the cardiovascular system" 30 : 825-834, 1995

11 Andersson IJ, "Increased atherosclerotic lesion area in apoE deficient mice overexpressing bovine growth hormone" 188 : 331-340, 2006

12 Rudling M, "Importance of growth hormone for the induction of hepatic low density lipoprotein receptors" 89 : 6983-6987, 1992

13 Fisker S, "Growth hormone(GH)substitution for one year normalizes elevated GH-binding protein levels in GH-deficient adults secondary to a reduction in body fat. A placebo-controlled trial" 8 : 105-112, 1998

14 Takahashi Y, "Growth hormone reverses nonalcoholic steatohepatitis in a patient with adult growth hormone deficiency" 132 : 938-943, 2007

15 Rudling M, "Growth hormone reduces plasma cholesterol in LDL receptor-deficient mice" 15 : 1350-1356, 2001

16 Binay C, "Growth hormone and the risk of atherosclerosis in growth hormone-deficient children" 25 : 294-297, 2015

17 Caicedo D, "Growth Hormone(GH)and Cardiovascular System" 19 : 290-, 2018

18 Nishikawa S, "Gene expression in livers of BALB/C and C57BL/6J mice fed a high-fat diet" 40 : 71-82, 2012

19 Skaggs SR, "Exogenous human growth hormone reduces body fat in obese women" 35 : 19-24, 1991

20 Kargi AY, "Diagnosis and treatment of growth hormone deficiency in adults" 9 : 335-345, 2013

21 Graham MR, "Changes in endothelial dysfunction and associated cardiovascular disease morbidity markers in GH-IGF axis pathology" 9 : 371-381, 2009

22 Di Somma C, "Cardiovascular alterations in adult GH deficiency" 31 : 25-34, 2017

23 Febbraio M, "CD36 : a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism" 108 : 785-791, 2001